Still-in-stealth biotech partners with Sloan Kettering scientists to make personalized cancer therapy more ‘public’ – Endpoints News

Still-in-stealth biotech partners with Sloan Kettering scientists to make personalized cancer therapy more ‘public’ – Endpoints News

If the pleasantries exchanged nowadays between the Biogen board and CEO Michel Vounatsos appeared somewhat intricately scripted to you, even by means of company PR requirements, their 10Q filed with the SEC gives a conceivable glimpse as to why.

It explains simply how meticulous they’ve been to steer clear of any unpleasantries throughout his lengthy good-bye as the corporate hunts a successor.

Consistent with a letter filed with the 10Q, the 2 events got here to an settlement in regards to the inventory Vounatsos will get subsequent February throughout their vesting date. A lot of the inventory will likely be given on a pro-rated foundation now, according to how a lot time he fulfilled by the point he leaves — fairly than lose the stocks because of his departure forward of the vesting date.

Stay studying Endpoints with a loose subscription

Liberate this tale in an instant and sign up for 141,100+ biopharma execs studying Endpoints day-to-day — and it is loose.


Leave a Comment

Your email address will not be published.